


## ONLINE SUPPLEMENTARY DATA

Supplementary Figure 1. Patient selection flow.



**Supplementary Table 1.** Benefit of remission over low disease activity, defined by DAS28, SDAI and CDAI, on work and activity impairment in RA patients.

Composite disease activity score	Total patients (n=1274)		Employed patients (n=451)			
	Activity impairment		Absenteeism		Presenteeism	
	Estimate (95% CI)	p	Estimate (95% CI)	p	Estimate (95% CI)	p
<b>DAS28</b>						
Remission vs. LDA	-3.95 (-6.67, -1.22)	<0.01	-1.63 (-3.69, 0.43)	0.12	-5.63 (-10.02, -1.24)	0.01
<b>SDAI</b>						
Remission vs. LDA	-3.00 (-5.88, -0.12)	0.04	-0.18 (-2.61, 2.25)	0.88	-3.13 (-7.85, 1.58)	0.19
<b>CDAI</b>						
Remission vs. LDA	-4.20 (-7.10, -1.30)	<0.01	-0.54 (-2.92, 1.84)	0.66	-4.41 (-8.99, 0.17)	0.06

Adjusted for propensity score including age, sex, RA disease duration, comorbidity positivity, pain VAS, EQ5D and use of methotrexate, other csDMARDs, biologic agents, and oral corticosteroid.

DAS28, disease activity index-28 joints; SDAI, simple disease activity index; CDAI, clinical disease activity index; CI, confidence interval; LDA, low disease activity; VAS, visual analogue scale; EQ5D, EuroQol-5 dimension; csDMARDs, conventional synthetic disease modifying anti-rheumatic drugs.